• By ICR Secretariat
  • Posted Thursday, September 8, 2022

Boehringer Ingelheim finally has skin in the game, scoring its first dermatology FDA nod


When the subject is skin disorders, Boehringer Ingelheim isn’t the first company that comes to mind. But Thursday, the world’s largest privately owned pharma became the first company to score an FDA approval to treat generalized pustular psoriasis (GPP), a rare and life-threatening skin condition that causes eruptions of painful blisters. These GPP flares are so disruptive to the system that they can trigger heart failure, renal failure or sepsis.